Background Erlotinib is a drug used for the treatment of non-small cell lung cancer (NSCLC)
and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients …

Drug-induced liver injury (DILI) is a common occurrence in clinical practice in the present
era because of frequent use of drugs and increase in patients who have increased …

Objective. Gefitinib often induces liver damage. A few reports have described that the
subsequent administration of erlotinib was associated with less hepatotoxicity, but the safety …

Non-small-cell lung cancer (NSCLC) and pancreatic cancer represent two major causes of
cancer-related morbidity and mortality worldwide. Conventional cytotoxic agents seem to …

We describe the case of a never-smoker who received second-line erlotinib as a treatment
for his non-small cell lung cancer. Within one month, acute hepatic failure developed as well …

Gefitinib and erlotinib are commercially available epidermal growth factor receptor tyrosine
kinase inhibitors (EGFR-TKIs) that are widely used for the treatment of non-small-cell lung …

INTRODUCTION: Hepatotoxicity secondary to gefitinib, an oral tyrosine kinase inhibitor (TKI)
against the epidermal growth factor receptor (EGFR), is under-appreciated, even though it …

Introduction Gefitinib and erlotinib have minor differences in their chemical structures, and
thus it remains unclear whether the hepatotoxicity induced by one compound is affected by …

Erlotinib is a tyrosine kinase inhibitor recently approved by the Food and Drug
Administration for the treatment of non–small-cell lung cancer and pancreatic cancer. We …

Objective: To report a case of erlotinib-induced hepatitis complicated by fatal lactic acidosis
in an elderly patient with lung adenocarcinoma and diabetes mellitus. Case Summary: A 77 …